Skip Navigation


NDT Advance Access originally published online on June 14, 2005
Nephrology Dialysis Transplantation 2005 20(8):1533-1539; doi:10.1093/ndt/gfh920
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/8/1533    most recent
gfh920v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nagy, J.
Right arrow Articles by Wittmann, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagy, J.
Right arrow Articles by Wittmann, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Editorial Comment

Renal protection in IgA nephropathy requires strict blood pressure control

Judit Nagy, Tibor Kovács and István Wittmann

Second Department of Medicine and Nephrological Center, Faculty of Medicine, University of Pécs, Hungary

Correspondence and offprint requests to: Judit Nagy, Second Department of Medicine and Nephrological Center, Faculty of Medicine, University of Pécs, H-7624 Pécs, Pacsirta str. 1. Hungary. Email: judit.nagy@aok.pte.hu

Keywords: ambulatory blood pressure monitoring; hypertension; IgA nephropathy; progression of renal diseases; renin–angiotensin–aldosterone system; renoprotection

The first 150 words of the full text of this article appear below.



   Introduction
 
Primary IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide [1,2]. Although IgAN was considered a benign condition for many years, we now know that many cases eventually progress to end-stage renal failure. According to recent reviews, the actuarial renal survival at 10 years is 80–85% in most studies. Moreover, 30–40% of affected individuals develop end-stage renal failure within 20 years from the apparent onset of the disease [1,2]. Impairment of renal function, severe proteinuria and arterial hypertension are the strongest predictors of an unfavourable outcome. Among histological parameters, proliferative glomerulonephritis with crescents or advanced lesions (glomerulosclerosis and interstitial fibrosis) are the most reliable prognostic markers. Despite considerable progress in our understanding of IgA biology, the aetiology and fundamental pathogenic mechanisms of mesangial IgA deposition have remained unsolved [2]. For this reason, treatment options of IgAN patients . . . [Full Text of this Article]



   Epidemiology and pathophysiology of hypertension in IgAN
 


   Value of 24 h ABPM
 


   Target blood pressure
 


   Treatment directed at the renin–angiotensin–aldosterone system (RAAS)
 


   Conclusion
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
E. N. Wardle
Renal protection in immunoglobulin-A nephropathy
Nephrol. Dial. Transplant., April 1, 2006; 21(4): 1136 - 1136.
[Full Text] [PDF]